Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnormality in AML, detectable in blast cells from about...

Full description

Saved in:
Bibliographic Details
Main Authors: Greiner, Jochen (Author) , Mohamed, Eithar (Author) , Fletcher, Daniel M. (Author) , Schuler, Patrick (Author) , Schrezenmeier, Hubert (Author) , Götz, Marlies (Author) , Guinn, Barbara (Author)
Format: Article (Journal)
Language:English
Published: 10 October 2024
In: Cancers
Year: 2024, Volume: 16, Issue: 20, Pages: 1-19
ISSN:2072-6694
DOI:10.3390/cancers16203443
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16203443
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/20/3443
Get full text
Author Notes:Jochen Greiner, Eithar Mohamed, Daniel M. Fletcher, Patrick J. Schuler, Hubert Schrezenmeier, Marlies Götz and Barbara-ann Guinn

MARC

LEADER 00000caa a2200000 c 4500
001 1921661453
003 DE-627
005 20250717004942.0
007 cr uuu---uuuuu
008 250407s2024 xx |||||o 00| ||eng c
024 7 |a 10.3390/cancers16203443  |2 doi 
035 |a (DE-627)1921661453 
035 |a (DE-599)KXP1921661453 
035 |a (OCoLC)1528044208 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Greiner, Jochen  |d 1970-  |e VerfasserIn  |0 (DE-588)12086293X  |0 (DE-627)080933459  |0 (DE-576)292421478  |4 aut 
245 1 0 |a Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia  |c Jochen Greiner, Eithar Mohamed, Daniel M. Fletcher, Patrick J. Schuler, Hubert Schrezenmeier, Marlies Götz and Barbara-ann Guinn 
264 1 |c 10 October 2024 
300 |b Illustrationen 
300 |a 19 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.04.2025 
520 |a Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnormality in AML, detectable in blast cells from about one-third of adults with AML. AML NPM1mut is recognized as a separate entity in the World Health Organization classification of AML. Clinical and survival data suggest that patients with this form of AML often have a more favorable prognosis, which may be due to the immunogenicity created by the mutations in the NPM1 protein. Consequently, AML with NPM1mut can be considered an immunogenic subtype of AML. However, the underlying mechanisms of this immunogenicity and associated favorable survival outcomes need to be further investigated. Immune checkpoint molecules, such as the programmed cell death-1 (PD-1) protein and its ligand, PD-L1, play important roles in leukemogenesis through their maintenance of an immunosuppressive tumor microenvironment. Preclinical trials have shown that the use of PD-1/PD-L1 checkpoint inhibitors in solid tumors and lymphoma work best in novel therapy combinations. Patients with AML NPM1mut may be better suited to immunogenic strategies that are based on the inhibition of the PD-1 immune checkpoint pathway than patients without this mutation, suggesting the genetic landscape of patients may also inform best practice for the use of PD-1 inhibitors. 
650 4 |a acute myeloid leukemia 
650 4 |a immunogenic subtype 
650 4 |a immunotherapy 
650 4 |a NPM1 mutation 
650 4 |a programmed death ligand 1 
700 1 |a Mohamed, Eithar  |e VerfasserIn  |4 aut 
700 1 |a Fletcher, Daniel M.  |e VerfasserIn  |4 aut 
700 1 |a Schuler, Patrick  |d 1978-  |e VerfasserIn  |0 (DE-588)1057847127  |0 (DE-627)79530580X  |0 (DE-576)413859304  |4 aut 
700 1 |a Schrezenmeier, Hubert  |e VerfasserIn  |0 (DE-588)111741904  |0 (DE-627)682876747  |0 (DE-576)356239551  |4 aut 
700 1 |a Götz, Marlies  |e VerfasserIn  |4 aut 
700 1 |a Guinn, Barbara  |e VerfasserIn  |0 (DE-588)1297323467  |0 (DE-627)1853645699  |4 aut 
773 0 8 |i Enthalten in  |t Cancers  |d Basel : MDPI, 2009  |g 16(2024), 20, Artikel-ID 3443, Seite 1-19  |h Online-Ressource  |w (DE-627)614095670  |w (DE-600)2527080-1  |w (DE-576)313958548  |x 2072-6694  |7 nnas  |a Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia 
773 1 8 |g volume:16  |g year:2024  |g number:20  |g elocationid:3443  |g pages:1-19  |g extent:19  |a Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia 
856 4 0 |u https://doi.org/10.3390/cancers16203443  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2072-6694/16/20/3443  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250407 
993 |a Article 
994 |a 2024 
998 |g 1057847127  |a Schuler, Patrick  |m 1057847127:Schuler, Patrick  |d 910000  |d 911000  |e 910000PS1057847127  |e 911000PS1057847127  |k 0/910000/  |k 1/910000/911000/  |p 4 
999 |a KXP-PPN1921661453  |e 4697825144 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Jochen","role":"aut","family":"Greiner","display":"Greiner, Jochen"},{"role":"aut","given":"Eithar","family":"Mohamed","display":"Mohamed, Eithar"},{"family":"Fletcher","display":"Fletcher, Daniel M.","given":"Daniel M.","role":"aut"},{"display":"Schuler, Patrick","family":"Schuler","given":"Patrick","role":"aut"},{"role":"aut","given":"Hubert","family":"Schrezenmeier","display":"Schrezenmeier, Hubert"},{"given":"Marlies","role":"aut","display":"Götz, Marlies","family":"Götz"},{"given":"Barbara","role":"aut","display":"Guinn, Barbara","family":"Guinn"}],"note":["Gesehen am 07.04.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"10 October 2024"}],"title":[{"title":"Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia","title_sort":"Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemia"}],"language":["eng"],"physDesc":[{"extent":"19 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Jochen Greiner, Eithar Mohamed, Daniel M. Fletcher, Patrick J. Schuler, Hubert Schrezenmeier, Marlies Götz and Barbara-ann Guinn"]},"recId":"1921661453","id":{"doi":["10.3390/cancers16203443"],"eki":["1921661453"]},"relHost":[{"disp":"Immunotherapeutic potential of mutated NPM1 for the treatment of acute myeloid leukemiaCancers","language":["eng"],"part":{"volume":"16","extent":"19","text":"16(2024), 20, Artikel-ID 3443, Seite 1-19","pages":"1-19","year":"2024","issue":"20"},"note":["Gesehen am 27.05.2020"],"title":[{"title_sort":"Cancers","title":"Cancers"}],"origin":[{"dateIssuedDisp":"2009-","publisherPlace":"Basel","dateIssuedKey":"2009","publisher":"MDPI"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"614095670","pubHistory":["1.2009 -"],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"id":{"zdb":["2527080-1"],"issn":["2072-6694"],"eki":["614095670"]}}]} 
SRT |a GREINERJOCIMMUNOTHER1020